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Boca Raton Regional Hospital
•

Not-for-profit 400 bed advanced academic tertiary medical center

•

Recognized leader in:
– Cardiovascular Care
– Oncology
– Women’s Health
– Orthopedics
– Emergency Medicine
– Neurosciences

•

Predominantly elderly patient population

•

Highest ranked hospital in Palm Beach County
– Listed by U.S. News & World Report 2019-2020

•

Lynn Cancer Institute is one of the largest cancer programs in the state of Florida
and accredited by the American College of Surgeons

Presentation Objective

• Identify the benefits of utilizing a biosimilar compared
to a reference product in patients at the Lynn Cancer
Institute

Erythropoietin-Stimulating Agents (ESAs)

Chronic kidney
disease (CKD)
Chemotherapy
induced anemia
(CIA)

Epoetin alfa [package insert]. Thousand Oaks, CA: Amgen; 2000.
Epoetin alfa-epbx [package insert]. Lake Forest, IL: Hospira; 2018.

ESAs

Myelodysplastic
syndromes
(MDS)

Introduction
A biosimilar is a biological product that is:
• Highly similar to a reference product
• Contains no clinically meaningful differences in safety, purity, and
potency compared to it’s reference product

The approval process does not require independent
safety and efficacy analyses of the biosimilar
Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–677.

Introduction
Epoetin alfa-epbx was FDA approved in May 2018

Therapeutic substitution between epoetin alfa and
epoetin alfa-epbx has not been established
In the Lynn Cancer Institute, patients were transitioned
from epoetin alfa to epoetin alfa-epbx due to a cost
savings initiative
Epoetin alfa-epbx [package insert]. Lake Forest, IL: Hospira; 2018.

Previous Studies
EPOE 10-13 (SC), EPOE 10-01 (IV)
• Objective: Compare the safety and efficacy of epoetin alfa-epbx with
epoetin alfa in patients with CKD on hemodialysis
• Methods: Phase 3, randomized, double-blind controlled trials

• Patients: N=932
• 1º outcome: Difference between mean weekly hemoglobin levels and
mean weekly dose
• Results: Epoetin alfa-epbx demonstrated no clinically meaningful
differences in efficacy compared to epoetin alfa
Fishbane S, Singh B, Kumbhat S, Wisemandle WA, et al. Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of end-stage kidney disease. Am Soc Nephrol. 2018;13:1204-1214.
Fishbane S, Spinwitz B, Wisemandle WA, et al. Randomized controlled trial of subcutaneous epoetin alfa-epbx versus epoetin alfa in end-stage kidney disease. Kidney Int Reports. 2019;4:1235-1247.

Purpose

To analyze the effectiveness of epoetin
alfa-epbx in maintaining hemoglobin levels
in conditions that typically require ESAs

Study Design
Methods: Observational, retrospective, crossover study conducted at the Lynn
Cancer Institute from January 2019 through May 2019

Inclusion Criteria
• Diagnosed with CIA, CKD, or MDS
• First dose and frequency of epoetin alfa-epbx
matched epoetin alfa dose and frequency
• Received a minimum of 5 months of therapy

Exclusion Criteria
• Packed red blood
cells or IV iron
administration
during the study
period

Transitioning Period

Epoetin alfa
treatment
• > 2 months
of therapy
• > 3 doses

March 2019

• Transitioned
to an
equivalent
dosing
regimen

Epoetin alfaepbx treatment
• > 2 months
of therapy
• > 3 doses

Data Collection

Retrospective
chart review
ICD-10 code
generated
report

Data
recorded on
Excel
spreadsheet

Study Outcomes

Primary
Outcome

• The mean difference between hemoglobin levels collected
during epoetin alfa treatment and epoetin alfa-epbx treatment

• The rate of hemoglobin levels not maintained after
transitioning from epoetin alfa to epoetin alfa-epbx, defined
Secondary by an absolute difference of 1 g/dL
Outcome

Results

178 patients screened for
inclusion

136 excluded

42 included in
analysis

MDS: 18

CKD: 24

Results
Primary outcome: The mean difference between hemoglobin levels collected
during epoetin alfa treatment and epoetin alfa-epbx treatment

Mean Hemoglobin Levels
Epoetin alfa-epbx

9.72

Mean difference:
0.04 g/dL

Epoetin alfa

9.76

T-test p value:
0.5999
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Results

Secondary outcome: The
rate of hemoglobin levels not
maintained after transitioning
from epoetin alfa to epoetin
alfa-epbx, defined by an
absolute difference of 1 g/dL

12%

88%

Hgb not maintained

Hgb maintained

Conclusion
There was no statistically significant difference between
hemoglobin levels after transitioning to epoetin alfa-epbx

Hemoglobin levels were not maintained in 5 out of 42
(12%) patients after transitioning products

• 4 patients experienced a decrease in Hg levels
• 1 patient experienced an increase in Hg levels

Discussion
This trial demonstrates that transitioning to epoetin
alfa-epbx is associated with similar hemoglobin
levels in patients with CKD and MDS
• In 3 out of 5 patients where hemoglobin levels were not
maintained, disease progression was noted
Epoetin alfa-epbx is an efficacious agent for
patients diagnosed with CKD or MDS

Limitations
The disease states assessed are progressive conditions that
require dose alteration and produce inconsistent laboratory values
The data collection time frame limited the size of the study
population increasing the variability of the results
Results cannot be generalized to all patients receiving ESAs due
to the specific patient population studied

Limitations

The inclusion and exclusion criteria did not successfully
capture patients diagnosed with CIA
• Results would be predicted to be similar for this patient population

The average rate of patients that do not normally maintain
hemoglobin levels is unknown

Self Assessment
Which of the following is not a benefit of utilizing a
biosimilar? Select all that apply.
 Results in cost savings for both the institution and patient
 Are interchangeable with their prior reference product due to similar
efficacy and safety
 Retain the same approval indications as their prior reference product
 Expand treatment options

Self Assessment
Which of the following is not a benefit of utilizing a
biosimilar? Select all that apply.
 Results in cost savings for both the institution and patient
 Are interchangeable with their prior reference product due to similar

efficacy and safety


Retain the same approval indications as their prior reference product
 Expand treatment options
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